AbbVie Targets Hetero Over Generic Norvir Plans

Law360, New York (May 17, 2013, 6:18 PM EDT) -- AbbVie Inc. on Wednesday hit Hetero USA Inc. in Delaware federal court with allegations that the generics maker infringes several patents with its planned generic version of HIV treatment Norvir.

According to AbbvVie, Hetero’s abbreviated new drug application for 100-milligram generic ritonavir infringes five patents covering Norvir — U.S. Patent Numbers 7,148,359; 7,364,752; 8,268,349; 6,037,157; and 6,703,403.

“AbbVie will be substantially and irreparably damaged and harmed by the infringing activities … unless those activities are precluded by this court,” the complaint said. “AbbVie does not have...
To view the full article, register now.